Search results for "Promyelocytic"

showing 10 items of 56 documents

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

2019

Abstract Since the comprehensive recommendations for the management of acute promyelocytic leukemia (APL) reported in 2009, several studies have provided important insights, particularly regarding the role of arsenic trioxide (ATO) in frontline therapy. Ten years later, a European LeukemiaNet expert panel has reviewed the recent advances in the management of APL in both frontline and relapse settings in order to develop updated evidence- and expert opinion–based recommendations on the management of this disease. Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review contains specific recommendations for the …

Acute promyelocytic leukemiamedicine.medical_specialtymedicine.medical_treatmentImmunologyMEDLINETretinoinDiseaseHemorrhagic DisordersBiochemistryHemorrhagic disorderEuropean LeukemiaNetArsenic TrioxideLeukemia Promyelocytic AcutePregnancyRecurrenceHumansMedicineDisease management (health)Intensive care medicineSpecial ReportNeoadjuvant therapyAPL Differentiation SyndromeAgedbusiness.industryDisease ManagementCell BiologyHematologymedicine.diseasePractice Guidelines as TopicFemalebusinessBlood
researchProduct

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-0…

2016

The aim of this clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with chemotherapy and to assess the NPM1 status as biomarker for ATRA therapy in younger adult patients (18–60 years) with acute myeloid leukemia (AML). Patients were randomized for intensive chemotherapy with or without open-label ATRA (45 mg/m2, days 6–8; 15 mg/m2, days 9–21). Two cycles of induction therapy were followed by risk-adapted consolidation with high-dose cytarabine or allogeneic hematopoietic cell transplantation. Due to the open label character of the study, analysis was performed on an intention-to-treat (ITT) and a per-protocol (PP) basis. One thousand one hundred pati…

AdultMale0301 basic medicineAcute promyelocytic leukemiaOncologymedicine.medical_specialtyNPM1Adolescentmedicine.medical_treatmentTretinoinYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansddc:610ChemotherapyAcute myeloid leukemiaHematologyAll-trans retinoic acidbusiness.industryMyeloid leukemiaInduction ChemotherapyHematologyGeneral MedicineMiddle Agedmedicine.disease3. Good healthSurgerySurvival RateTransplantationClinical trialLeukemia Myeloid AcuteTreatment Outcome030104 developmental biologyNucleophosmin-1Acute myeloid leukemia; All-trans retinoic acid; Nucleophosmin-1030220 oncology & carcinogenesisCytarabineFemaleOriginal ArticlebusinessNucleophosminFollow-Up Studiesmedicine.drug
researchProduct

Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia

2014

Acute promyelocytic leukemia (APL) is characterized by the t(15;17)(q22;q21), but additional chromosomal abnormalities (ACA) and other rearrangements can contribute in the development of the whole leukemic phenotype. We hypothesized that some ACA not detected by conventional techniques may be informative of the onset of APL. We performed the high-resolution SNP array (SNP-A) 6.0 (Affymetrix) in 48 patients diagnosed with APL on matched diagnosis and remission sample. Forty-six abnormalities were found as an acquired event in 23 patients (48%): 22 duplications, 23 deletions and 1 Copy-Neutral Loss of Heterozygocity (CN-LOH), being a duplication of 8(q24) (23%) and a deletion of 7(q33-qter) (…

AdultMaleAcute promyelocytic leukemiamedicine.medical_specialtyAdolescentOncogene Proteins FusionMicroarrayslcsh:MedicineLoss of HeterozygosityChromosomal translocationBiologyResearch and Analysis MethodsPolymorphism Single NucleotideTranslocation GeneticHematologic Cancers and Related DisordersLoss of heterozygosityYoung AdultLeukemia Promyelocytic AcuteLeukemiasGene duplicationMedicine and Health SciencesmedicineHumanslcsh:ScienceAgedChromosome AberrationsChromosomes Human Pair 15Multidisciplinarylcsh:RBreakpointCytogeneticsBiology and Life SciencesComputational BiologyHematologyMiddle AgedPrognosismedicine.diseaseMolecular biologyLeukemiaBioassays and Physiological AnalysisKaryotypingCancer researchlcsh:QFemaleResearch ArticleChromosomes Human Pair 17SNP arrayPLoS ONE
researchProduct

How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

2014

Abstract Differentiation syndrome (DS), formerly known as retinoic acid syndrome, is a relatively common and potentially severe complication seen in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and/or arsenic trioxide. The full-blown syndrome consists of unexplained fever, weight gain, dyspnea with pulmonary infiltrates, pleuropericardial effusion, hypotension, and renal failure. Most measures currently used for management of DS have very little evidence-based support, and therefore, many remain controversial. Despite the lack of evidence supporting DS prophylaxis, several groups have adopted a preventive strategy with corticosteroids, especially for patie…

AdultMaleAcute promyelocytic leukemiamedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsPremedicationImmunologyTretinoinBiochemistryArsenicalslaw.inventionchemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcutelawTretinoinInternal medicinemedicineHumansArsenic trioxideIntensive care medicineDexamethasonebusiness.industryOxidesSyndromeCell BiologyHematologymedicine.diseaseIntensive care unitDiscontinuationRetinoic acid syndromeLeukemiachemistryFemalebusinessmedicine.drugBlood
researchProduct

Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients

2008

Background: Promyelocytic leukemia (PML) tumor suppressor gene plays a key role in acute PML pathogenesis but its involvement in pathogenesis and prognosis of solid cancers has not been defined yet. Patients and methods: In all, 62 ampullary adenocarcinoma patients who underwent curative surgery between 1996 and 2005 were included. Expression analysis of PML was carried out by immunohistochemical staining and correlated with disease-free survival (DFS) and overall survival (OS). Results: In 24 tumor specimens (38.7%), PML was classified as absent, in 16 (25.8%) as focally expressed and in 22 (35.5%) as diffusely expressed. By univariate analysis, DFS was significantly influenced by patholog…

AdultMaleOncologyAmpulla of Vatermedicine.medical_specialtyPathology(PML)ampullary cancerTumor suppressor geneCommon Bile Duct NeoplasmsAdenocarcinomaPromyelocytic Leukemia ProteinsurvivalCohort StudiesPathogenesispromyelocytic leukemia gene expressionPromyelocytic leukemia proteinampulla of vater cancer; promyelocytic leukemia gene expression; prognosisInternal medicineBiomarkers TumorHumansMedicinePathologicalAgedRetrospective StudiesAged 80 and overUnivariate analysisPMLbiologybusiness.industryTumor Suppressor ProteinsNuclear Proteinsampullary cancerHematologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisGene Expression Regulation NeoplasticLeukemiaOncologyPML; ampullary cancer; survivalbiology.proteinImmunohistochemistryT-stageampulla of vater cancerFemalebusinessTranscription FactorsAnnals of Oncology
researchProduct

PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy

2012

Soft tissue sarcomas are aggressive tumors representing <1% of all adult neoplasms. Aim of our study was to evaluate promyelocytic leukemia gene expression value as prognostic factor and as a factor predicting response to alkylating agents/antracycline-based first line therapy. One hundred eleven patients affected by locally advanced and metastatic soft tissue sarcoma were selected. PML expression was evaluated by immunohistochemical analysis in pathological samples and in the corresponding normal tissue from each case. PML immunohistochemical results were correlated with prognosis and with radiological response to alkylating agents/antracycline-based first line therapy. PML expression was …

AdultMaleOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical BiochemistryCellDown-RegulationSoft Tissue NeoplasmsPromyelocytic Leukemia ProteinLiposarcomaPleomorphic LiposarcomaYoung AdultPredictive Value of TestsInternal medicinemedicineHumansAnthracyclinesAntineoplastic Agents AlkylatingPathologicalAgedRetrospective StudiesAged 80 and overPMLbusiness.industryTumor Suppressor ProteinsSoft tissue sarcomaNuclear ProteinsSoft tissueSarcomaCell BiologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistrymedicine.anatomical_structuresoft tissue sarcomas; PMLDrug Resistance Neoplasmsoft tissue sarcomaImmunologyImmunohistochemistryFemaleSarcomabusinessTranscription Factors
researchProduct

Hepatitis C Virus Core Protein Inhibits Tumor Suppressor Protein Promyelocytic Leukemia Function in Human Hepatoma Cells

2005

Abstract Tumor suppressor protein promyelocytic leukemia (PML) is implicated in apoptosis regulation and antiviral response. PML localizes predominantly to PML-nuclear bodies (PML-NB), nuclear macromolecular complexes regulating tumor suppressor protein p53 activity. Consistent with the function of PML in the cellular antiviral response, PML-NBs represent preferential targets in viral infections. In the case of hepatitis C virus (HCV) infection, important characteristics are nonresponsiveness to IFN therapy and development of hepatocellular carcinoma. However, the mechanisms which lead to the development of hepatocellular carcinoma are largely unknown. Here, we show that HCV core protein lo…

Cancer ResearchCarcinoma HepatocellularTumor suppressor genevirusesApoptosisPromyelocytic Leukemia ProteinBiologyTransfectionmedicine.disease_causePromyelocytic leukemia proteinCell Line TumorCoactivatormedicineHumansProtein IsoformsPhosphorylationCell NucleusTumor Suppressor ProteinsViral Core ProteinsLiver NeoplasmsNuclear Proteinsvirus diseasesAcetylationFas receptorHepatitis Cdigestive system diseasesNeoplasm ProteinsOncologyApoptosisAcetylationbiology.proteinCancer researchPhosphorylationTumor Suppressor Protein p53CarcinogenesisTranscription FactorsCancer Research
researchProduct

Chimeric amplicons containing the c-myc gene in HL60 cells

1998

The major amplicon present in HL60 cells is chimeric in nature being composed of 70 kb of DNA sequence derived from the MYC locus linked to 80 kb of novel DNA sequence derived from a non contiguous region located telomeric to the c-myc gene at 8q24 (Feo et al., 1996). Here we show by fluorescence in situ hybridization (FISH) that these coamplified sequences, MCR (Myc Coamplified Region), are derived from a locus located 3-4 Mb telomeric to the c-myc gene in the q24.2-24.3 region of chromosome 8. Genomic cloning and Southern blot analysis indicate the arrangement of chimeric amplicons are in tandem arrays. Analysis of the DNA sequences at the juncture of the MYC locus and the MCR suggest tha…

Cancer ResearchOncogene Proteins FusionInverted repeatMolecular Sequence DataGenes mycHL-60 CellsLocus (genetics)BiologyMolecular cloningDNA sequencingLeukemia Promyelocytic AcuteGene mappingGeneticsHumansCloning MolecularMolecular BiologyGeneIn Situ Hybridization FluorescenceSouthern blotChromosome AberrationsRecombination GeneticGeneticsBase SequenceChromosome FragilityGene AmplificationSequence Analysis DNAAmpliconMolecular biologyBlotting SouthernChromosomes Human Pair 8Oncogene
researchProduct

IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53.

2009

Abstract IFNs are pleiotropic cytokines that have been shown to be important regulators of cell growth. IFN-α has recently been recognized to harbor therapeutic potential in prevention and treatment of hepatocellular carcinoma (HCC). However, HCC cells respond differentially to IFN treatment, the mechanism of which is largely unknown. To address this issue, we analyzed the effect of IFN-α on different liver tumor cell lines. We found that growth inhibiting effects of IFN-α in hepatoma cells require PML-NB induction and, moreover, tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) expression on the mRNA and protein level. RNAi silencing of PML down-regulates TRAIL expression in …

Cancer ResearchProgrammed cell deathCarcinoma HepatocellularTumor suppressor genemedicine.medical_treatmentApoptosisPromyelocytic Leukemia ProteinTNF-Related Apoptosis-Inducing LigandPromyelocytic leukemia proteinMiceCell Line TumormedicineGene silencingAnimalsHumansRNA MessengerbiologyCell growthTumor Suppressor ProteinsLiver NeoplasmsInterferon-alphaNuclear ProteinsCytokineOncologyApoptosisbiology.proteinCancer researchTumor necrosis factor alphaRNA InterferenceTumor Suppressor Protein p53Transcription FactorsCancer research
researchProduct

Reorganization of Nuclear Domain 10 Induced by Papillomavirus Capsid Protein L2

2002

AbstractNuclear domains (ND) 10 are associated with proteins implicated in transcriptional regulation, growth suppression, and apoptosis. We now show that the minor capsid protein L2 of human papillomavirus (HPV) type 33 induces a reorganization of ND10-associated proteins. Whereas the promyelocytic leukemia protein, the major structural component of ND10, was unaffected by L2, Sp100 was released from ND10 upon L2 expression. The total cellular amount of Sp100, but not of Sp100 mRNA, decreased significantly, suggesting degradation of Sp100. Proteasome inhibitors induced the dispersal of Sp100 and inhibited the nuclear translocation of L2. In contrast to Sp100, Daxx was recruited to ND10 by …

Co-Repressor ProteinsImmunoprecipitationFluorescent Antibody TechniqueVaccinia virusPromyelocytic Leukemia ProteinAutoantigenspapillomavirusCell LinePromyelocytic leukemia proteinCapsidDeath-associated protein 6DaxxVirologyHumansSp100RNA MessengerAdaptor Proteins Signal TransducingCell NucleusRecombination GeneticbiologyTumor Suppressor ProteinsIntracellular Signaling Peptides and ProteinsNuclear ProteinsND10Signal transducing adaptor proteinAntigens NuclearOncogene Proteins ViralL2biochemical phenomena metabolism and nutritionBlotting NorthernMolecular biologyNeoplasm ProteinsTransport proteinCell biologyProtein TransportProteasomeCapsidbiology.proteinRNACapsid ProteinsFemaleCarrier ProteinsCo-Repressor ProteinsMolecular ChaperonesTranscription FactorsVirology
researchProduct